EDAP has been the topic of a number of other research reports. TheStreet downgraded Edap Tms from a “b-” rating to a “d+” rating in a report on Monday, June 17th. Zacks Investment Research upgraded Edap Tms from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Finally, HC Wainwright set a $7.00 price objective on Edap Tms and gave the stock a “buy” rating in a report on Tuesday, June 11th.
NASDAQ:EDAP remained flat at $$3.23 during mid-day trading on Friday. The company had a trading volume of 36,957 shares, compared to its average volume of 178,629. The company has a fifty day moving average of $2.94 and a 200 day moving average of $3.31. Edap Tms has a 12-month low of $1.35 and a 12-month high of $5.42. The company has a market cap of $93.37 million, a PE ratio of 161.25 and a beta of 1.76. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.97 and a current ratio of 2.40.
A number of institutional investors have recently made changes to their positions in the business. Fosun International Ltd boosted its position in Edap Tms by 9.4% during the second quarter. Fosun International Ltd now owns 397,568 shares of the medical equipment provider’s stock worth $1,145,000 after purchasing an additional 34,083 shares during the period. Morgan Stanley boosted its position in Edap Tms by 222.7% during the second quarter. Morgan Stanley now owns 267,408 shares of the medical equipment provider’s stock worth $722,000 after purchasing an additional 184,539 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Edap Tms in the second quarter valued at approximately $607,000. Susquehanna International Group LLP boosted its position in shares of Edap Tms by 762.9% in the second quarter. Susquehanna International Group LLP now owns 205,178 shares of the medical equipment provider’s stock valued at $556,000 after acquiring an additional 181,401 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in shares of Edap Tms in the second quarter valued at approximately $282,000. 11.77% of the stock is owned by hedge funds and other institutional investors.
Edap Tms Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Featured Story: Federal Reserve
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.